Annovis Bio (ANVS) Competitors $5.02 +0.01 (+0.20%) As of 01/17/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ANVS vs. CGC, ACIU, CADL, CCCC, FHTX, BNTC, URGN, ATAI, LFCR, and HRTXShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include Canopy Growth (CGC), AC Immune (ACIU), Candel Therapeutics (CADL), C4 Therapeutics (CCCC), Foghorn Therapeutics (FHTX), Benitec Biopharma (BNTC), UroGen Pharma (URGN), Atai Life Sciences (ATAI), Lifecore Biomedical (LFCR), and Heron Therapeutics (HRTX). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Canopy Growth AC Immune Candel Therapeutics C4 Therapeutics Foghorn Therapeutics Benitec Biopharma UroGen Pharma Atai Life Sciences Lifecore Biomedical Heron Therapeutics Canopy Growth (NASDAQ:CGC) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends. Which has preferable earnings & valuation, CGC or ANVS? Annovis Bio has lower revenue, but higher earnings than Canopy Growth. Annovis Bio is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCanopy Growth$220.27M1.08-$487.23M-$4.93-0.44Annovis BioN/AN/A-$56.20M-$4.46-1.13 Do analysts recommend CGC or ANVS? Canopy Growth presently has a consensus target price of $3.50, indicating a potential upside of 60.55%. Annovis Bio has a consensus target price of $31.40, indicating a potential upside of 525.50%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than Canopy Growth.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 2 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.33Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility and risk, CGC or ANVS? Canopy Growth has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Does the media refer more to CGC or ANVS? In the previous week, Annovis Bio had 3 more articles in the media than Canopy Growth. MarketBeat recorded 3 mentions for Annovis Bio and 0 mentions for Canopy Growth. Annovis Bio's average media sentiment score of 0.38 beat Canopy Growth's score of 0.33 indicating that Annovis Bio is being referred to more favorably in the news media. Company Overall Sentiment Canopy Growth Neutral Annovis Bio Neutral Do insiders and institutionals hold more shares of CGC or ANVS? 3.3% of Canopy Growth shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 1.3% of Canopy Growth shares are held by insiders. Comparatively, 32.3% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer CGC or ANVS? Annovis Bio received 10 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 96.77% of users gave Annovis Bio an outperform vote while only 19.23% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformCanopy GrowthOutperform Votes2019.23%Underperform Votes8480.77% Annovis BioOutperform Votes3096.77% Underperform Votes13.23% Is CGC or ANVS more profitable? Annovis Bio has a net margin of 0.00% compared to Canopy Growth's net margin of -186.17%. Annovis Bio's return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Canopy Growth-186.17% -74.29% -29.94% Annovis Bio N/A N/A -311.00% SummaryAnnovis Bio beats Canopy Growth on 15 of the 18 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$69.28M$6.22B$5.21B$19.94BDividend YieldN/A2.94%5.13%3.71%P/E Ratio-1.139.9189.4241.41Price / SalesN/A309.211,240.0416.25Price / CashN/A61.4443.7519.84Price / Book-6.886.055.315.76Net Income-$56.20M$154.90M$122.54M$993.25M7 Day Performance7.73%1.35%1.42%2.27%1 Month Performance14.87%0.41%2.51%4.76%1 Year Performance-57.09%3.08%25.29%18.83% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.0643 of 5 stars$5.02+0.2%$31.40+525.5%-57.1%$69.28MN/A-1.133CGCCanopy Growth3.2078 of 5 stars$2.39-2.4%$3.50+46.4%-50.1%$260.37M$280.50M-0.483,150ACIUAC Immune2.2523 of 5 stars$2.61-4.0%$12.00+359.8%-35.4%$258.23M$40.97M-5.67140Positive NewsCADLCandel Therapeutics3.4112 of 5 stars$7.77-5.0%$19.00+144.5%+416.3%$252.34M$120,000.00-4.4960Insider TradePositive NewsCCCCC4 Therapeutics2.0809 of 5 stars$3.50-4.6%$10.67+204.8%-33.3%$247.06M$33.67M-2.06150FHTXFoghorn Therapeutics2.7018 of 5 stars$4.37+1.6%$13.80+215.8%+12.2%$242.94M$25.52M-2.28120Positive NewsGap DownBNTCBenitec Biopharma2.8703 of 5 stars$10.39-5.5%$24.43+135.1%+261.4%$241.21M$80,000.00-3.6620Positive NewsURGNUroGen Pharma3.948 of 5 stars$10.18-0.6%$43.70+329.3%-30.5%$238.76M$89.36M-3.23200Positive NewsGap DownATAIAtai Life Sciences2.0442 of 5 stars$1.42-5.3%$9.00+533.8%-14.1%$238.28M$331,000.00-1.7580LFCRLifecore Biomedical1.7663 of 5 stars$6.36+1.1%$8.00+25.8%-7.8%$235.48M$130.86M79.50690Short Interest ↑HRTXHeron Therapeutics3.9355 of 5 stars$1.54-0.6%$5.67+268.0%-22.0%$234.23M$137.74M-8.56300Analyst UpgradePositive News Related Companies and Tools Related Companies Canopy Growth Competitors AC Immune Competitors Candel Therapeutics Competitors C4 Therapeutics Competitors Foghorn Therapeutics Competitors Benitec Biopharma Competitors UroGen Pharma Competitors Atai Life Sciences Competitors Lifecore Biomedical Competitors Heron Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:ANVS) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
